Christian Gaebler

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1098730/publications.pdf

Version: 2024-02-01

37 papers	12,675 citations	186209 28 h-index	330025 37 g-index
64 all docs	64 docs citations	64 times ranked	18678 citing authors

#	Article	IF	Citations
1	Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature, 2020, 584, 437-442.	13.7	1,742
2	Evolution of antibody immunity to SARS-CoV-2. Nature, 2021, 591, 639-644.	13.7	1,355
3	Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. ELife, 2020, 9, .	2.8	1,239
4	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature, 2021, 592, 616-622.	13.7	1,232
5	Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. Cell, 2020, 182, 828-842.e16.	13.5	724
6	Vaccine Breakthrough Infections with SARS-CoV-2 Variants. New England Journal of Medicine, 2021, 384, 2212-2218.	13.9	647
7	Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature, 2021, 595, 426-431.	13.7	610
8	Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. Journal of Experimental Medicine, 2020, 217, .	4.2	503
9	Somatic Mutations of the Immunoglobulin Framework Are Generally Required for Broad and Potent HIV-1 Neutralization. Cell, 2013, 153, 126-138.	13.5	478
10	HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature, 2012, 492, 118-122.	13.7	463
11	Enhanced SARS-CoV-2 neutralization by dimeric IgA. Science Translational Medicine, 2021, 13, .	5.8	379
12	Plasma Neutralization of the SARS-CoV-2 Omicron Variant. New England Journal of Medicine, 2022, 386, 599-601.	13.9	371
13	Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies. Nature Communications, 2021, 12, 4196.	5.8	332
14	Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. Nature, 2021, 600, 517-522.	13.7	239
15	Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. Immunity, 2021, 54, 1853-1868.e7.	6.6	230
16	Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost. Nature, 2022, 607, 128-134.	13.7	197
17	High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape. Nature, 2021, 600, 512-516.	13.7	174
18	Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. Journal of Experimental Medicine, 2012, 209, 1469-1479.	4.2	156

#	Article	IF	Citations
19	Persistent cellular immunity to SARS-CoV-2 infection. Journal of Experimental Medicine, 2021, 218, .	4.2	115
20	Recommendations for measuring HIV reservoir size in cure-directed clinical trials. Nature Medicine, 2020, 26, 1339-1350.	15.2	96
21	Combination of quadruplex qPCR and next-generation sequencing for qualitative and quantitative analysis of the HIV-1 latent reservoir. Journal of Experimental Medicine, 2019, 216, 2253-2264.	4.2	92
22	Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins. Immunity, 2022, 55, 998-1012.e8.	6.6	86
23	Antigen-responsive CD4+ T cell clones contribute to the HIV-1 latent reservoir. Journal of Experimental Medicine, 2020, 217, .	4.2	75
24	Prolonged viral suppression with anti-HIV-1 antibody therapy. Nature, 2022, 606, 368-374.	13.7	75
25	ReScan, a Multiplex Diagnostic Pipeline, Pans Human Sera for SARS-CoV-2 Antigens. Cell Reports Medicine, 2020, 1, 100123.	3.3	70
26	Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York. Nature Communications, 2021, 12, 4886.	5.8	65
27	Longitudinal clonal dynamics of HIV-1 latent reservoirs measured by combination quadruplex polymerase chain reaction and sequencing. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	52
28	Sequence Evaluation and Comparative Analysis of Novel Assays for Intact Proviral HIV-1 DNA. Journal of Virology, 2021, 95, .	1.5	47
29	Integration features of intact latent HIV-1 in CD4+ T cell clones contribute to viral persistence. Journal of Experimental Medicine, 2021, 218, .	4.2	32
30	All eyes on a hurdle race for a SARS-CoV-2 vaccine. Nature, 2020, 586, 501-502.	13.7	23
31	TOP-Plus Is a Versatile Biosensor Platform for Monitoring SARS-CoV-2 Antibody Durability. Clinical Chemistry, 2021, 67, 1249-1258.	1.5	12
32	Antibody evolution to SARS-CoV-2 after single-dose Ad26.COV2.S vaccine in humans. Journal of Experimental Medicine, 2022, 219, .	4.2	10
33	Isolation of HIV-1-reactive antibodies using cell surface-expressed gp160Î”cBaL. Journal of Immunological Methods, 2013, 397, 47-54.	0.6	8
34	COVID-19 antibody development fueled by HIV-1 broadly neutralizing antibody research. Current Opinion in HIV and AIDS, 2021, 16, 25-35.	1.5	7
35	Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization After Messenger RNA Vaccination and Variant Breakthrough Infection. Open Forum Infectious Diseases, 2022, 9, .	0.4	5
36	Engineered extracellular matrix components do not alter the immunomodulatory properties of mesenchymal stromal cellsin vitro. Journal of Tissue Engineering and Regenerative Medicine, 2013, 7, 921-924.	1.3	4

#	Article	IF	Citations
37	Broadly Neutralizing Antihuman Immunodeficiency Virus Antibodies in Infants: Promising New Tools for Prevention of Mother-to-Child Transmission?. Journal of Infectious Diseases, 2020, 222, 525-527.	1.9	1